Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)

Market Cap	4.86B
Revenue (ttm)	511.66M
Net Income (ttm)	138.62M
Shares Out	146.32M
EPS (ttm)	0.93
PE Ratio	35.76
Forward PE	n/a
Dividend	1.07 (3.25%)
Ex-Dividend Date	Jun 6, 2025

Volume	652,408
Average Volume	1,432,977
Open	33.01
Previous Close	32.92
Day's Range	32.38 - 33.26
52-Week Range	16.70 - 35.68
Beta	0.54
RSI	55.48
Earnings Date	Sep 5, 2025

About Hangzhou Biotest Biotech

Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, biochemistry, and various infectious diseases. It also provides veterinary test kits; fluorescence immunoassay rapid test kits; and other rapid testing kits. The company was founded in 2008 and is based in Hangzhou, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 603
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688767

Financial Performance

In 2024, Hangzhou Biotest Biotech's revenue was 559.40 million, an increase of 26.53% compared to the previous year's 442.11 million. Earnings were 169.52 million, an increase of 59.01%.